Dermatology and therapy · 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eyerich Kilian, Mendes-Bastos Pedro, Holzer Gregor, Jain Vipul, Katoh Norito, Luna Paula C, Segura Pablo Coto, Lane Michael, Grada Ayman, Moreira Alvaro, Bunick Christopher G
Аннотация
INTRODUCTION: Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).
METHODS: Patients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index [EASI]) received upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 [almost clear], EASI 90 [near-complete clearance], EASI 100 [complete clearance], and patient-reported outcomes [PROs]) through week 16.
RESULTS: At week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15 mg (46.8%, 41.9%, 29.1%) and upadacitinib 30 mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15 mg and 96.3% for upadacitinib 30 mg.
CONCLUSIONS: Upadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement.
TRIAL REGISTRATION: ClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).
METHODS: Patients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index [EASI]) received upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 [almost clear], EASI 90 [near-complete clearance], EASI 100 [complete clearance], and patient-reported outcomes [PROs]) through week 16.
RESULTS: At week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15 mg (46.8%, 41.9%, 29.1%) and upadacitinib 30 mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15 mg and 96.3% for upadacitinib 30 mg.
CONCLUSIONS: Upadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement.
TRIAL REGISTRATION: ClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).